Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Date:11/15/2010

ient compared with 4.5 days per patient in the placebo group. This finding is especially noteworthy because heart failure is the leading cause of hospitalization in Americans 65 and older.

Additionally, the 12-month CUPID data show that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained the same while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

"We believe the clear safety and efficacy sustained in patients over a 12-month period strongly support the continued development of MYDICAR for a Phase 3 study and commercialization," said Krisztina Zsebo, Ph.D., President and CEO of Celladon. "The clinical deterioration seen in the placebo patients receiving ongoing optimal standard therapy emphasizes the tremendous unmet medical need in people with advanced heart failure. Based on these results we are encouraged that MYDICAR can fill this need."  

The CUPID Trial

The CUPID trial (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. Enrolled patients had severe forms of the disease defined by New York Heart Association Class III or IV heart failure, significantly impaired pumping function of their hearts (ejection fraction < 35 percent), and less than half the normal ability to transport and utilize oxygen during exercise testing (VO2max < 20 mL/kg/min). The CUPID trial ClinicalTrials.gov Identifier is NCT00454818.

Primary outcome measures included safety, worsening of heart failure leading to hospitalization, f
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "Alzheimer ...  to their offering.       (Logo: ... challenge in management. With nearly 8 million ... major markets of the world and anticipated ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... information services, announced that it is scheduled to speak ... York.  Steve Rusckowski , the company,s President and ... point strategy.  The presentation is scheduled for Tuesday, June ... The presentation will be webcast live during the conference ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/26qndf/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology by ... Nanotechnology will be applied at all stages ... optimal delivery to diagnostic applications in clinical ...
(Date:5/28/2015)... , May 27, 2015 Research ... of Jain PharmaBiotech,s new report "Cell Therapy ... offering. This report describes and evaluates ... started to play an important role in the ... replacing the old fashioned bone marrow transplants. Role ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... MOUNTAIN VIEW, Calif., Oct. 14 Clontech Laboratories,Inc., ... the three,winners of the 2008 Nobel Prize in ... Tsien, for the discovery and development of the ... related fluorescent proteins.,The application of fluorescent proteins as ...
... America, Inc. and its,subsidiary Sysmex Canada, Inc. today ... from MOLIS WAM to Sysmex WAM. The new,name ... Sysmex brand,architecture., "Sysmex WAM is one of ... the hematology automation systems market today," explains Ralph,Taylor, ...
... Solos Endoscopy, Inc. (OTC,Pink Sheets: SNDY) is pleased ... to upgrade its status on the Pinksheets Electronic OTC ... in the process,of completing their Issuer Information Statement, which ... expects to have its status,upgraded by the end of ...
Cached Biology Technology:Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry 2Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 2
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... from the melting Arctic ice cap told Jeff Chanton and ... there is a release of methane, a powerful greenhouse gas ... how much, said Chanton, the John W. Winchester Professor of ... whose findings were published in the respected journal Nature ...
... PORTOLA VALLEY, Calif., June 18, 2012 Spectros Corporation ... for viewing real-time patient results on T-Stat white light ... healthcare by improving patient monitoring and decreasing the delayed ... awaited an easy and simple approach to remote monitoring ...
... of surfaces in hotel rooms finds television remotes to ... items on housekeeping carts carry the potential to cross-contaminate ... the findings today at the 2012 General Meeting of ... obligation to provide their guests with a safe and ...
Cached Biology News:Study: Seeking Arctic methane has serious implications for Florida coastline 2Spectros Launches OnCall Wireless Remote Access for T-Stat 2The most contaminated surfaces in hotel rooms 2
... Ultrasonic Nebulizers are available in two product models ... these two models is that the 6000AT+ includes ... a drier aerosol for improved detection limits and ... for a range of elements by 10-40 times. ...
... Cetac Ultrasonic Nebulizers are available in two product ... between these two models is that the 6000AT+ ... create a drier aerosol for improved detection limits ... limits for a range of elements by 10-40 ...
... from Thermus aquaticus (strain YT1) is ... then highly purified to produce Taq ... the amplification and sequence testing of ... the Taq DNA polymerase has been ...
Request Info...
Biology Products: